Non-small cell lung carcinoma patients harboring ALK gene rearrangement have been reported to benefit from tyrosine kinase inhibitor treatment [3–6], which makes the reliable screening of ALK fusions important. The gene discussed is ALK; the disease is non-small cell lung carcinoma.